Manifold Bio, a Boston-based start-up spun out of George Church’s lab at Harvard University and the Wyss Institute for Biologically Inspired Engineering, has raised $40 million in series A funding. PharmiWeb: Manifold Bio Expands Leadership Team to Drive its AI + In Vivo Targeted Biologics Platform BOSTON--(BUSINESS WIRE)--Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with massively multiplexed in vivo measurement, today announced the expansion of its ... Manifold Bio Expands Leadership Team to Drive its AI + In Vivo Targeted Biologics Platform Business Wire: Manifold Bio Raises $40 Million Series A to Expand In Vivo Biologics Design Platform BOSTON--(BUSINESS WIRE)--Manifold Bio, a next-generation protein therapeutics company pioneering an in vivo biologics design platform, today announced the close of a $40 million Series A financing ...
Manifold Bio Raises $40 Million Series A to Expand In Vivo Biologics Design Platform MarketWatch: Manifold Bio Demonstrates Million-Scale Experimental Validation of AI-Driven Protein Binder Design with NVIDIA Manifold Bio, a platform therapeutics company pioneering direct-to-vivo drug discovery, today announced a joint study with NVIDIA to validate Proteina-Complexa, NVIDIA's generative model for protein ... Manifold Bio Demonstrates Million-Scale Experimental Validation of AI-Driven Protein Binder Design with NVIDIA Yahoo: Manifold Bio's molecular 'barcodes' could break through pharma's in vivo bottleneck
